DMAC Stock Analysis: Buy, Sell, or Hold?
DMAC - DiaMedica Therapeutics Inc. Common Stock
$6.52
0.18 (2.84%)
▲
5d:
-3.26%
30d:
-14.44%
90d:
+5.5%
BUY
HIGH Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 11, 2026
6d
Get Alerted When DMAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DMAC shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: DMAC shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: DMAC is currently trading at $6.52, which is considered oversold relative to its 30-day fair value range of $6.64 to $7.66.
Technical Outlook: Technically, DMAC is showing sideways momentum. Immediate support is located at $6.25, while resistance sits at $7.14.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.50 (+137.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DMAC is showing sideways momentum. Immediate support is located at $6.25, while resistance sits at $7.14.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.50 (+137.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.64 -
$7.66
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 137.7% below Wall St target ($15.50)
Trading Range Analysis
30-Day Trading Range
$6.64 -
$7.66
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.09
(16.7%)
Support & Resistance Levels
Support Level
$6.25
Resistance Level
$7.14
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.41
Wall Street Target
$15.50
(+137.7%)
Share & Embed Analysis
Last updated: August 04, 2026 9:06 AM ET
Data refreshes hourly during market hours. Next update: 10:06 AM
Data refreshes hourly during market hours. Next update: 10:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DMAC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
